FCGR2A and neoplasm: Studies performed in vitro with human cells and in vivo preclinical models suggest that FcγR binding induces activation of NK cells and antigen-presenting cells and depletes TIGIT-expressing Treg cells and tumor cells through direct antibody-dependent cell-mediated cytotoxicity (19, 33).